Biosimilars Training Program

GCCA and the World Patients Alliance partnered to develop an educational resource about biosimilars policy for patient advocates across all diseases.

Biosimilars Training Program

What are biosimilars?

Biosimilars, also known as follow-on biologics, are medicines that are similar, but not identical, to an original biologic medicine. Biologic medicines are used in the treatment of many types of cancer, including breast, lung, and colorectal cancers, and in the treatment of chronic autoimmune and inflammatory diseases such as rheumatoid arthritis, psoriasis, multiple sclerosis, and Crohn’s disease. There are some debates about how biosimilars should be treated in terms of interchangeability and substitutions, treatment switching decision-making, and medicine naming. GCCA supports the approval and introduction of biosimilars as a tool to lower costs and increase access to biologic therapies and believes that robust regulatory oversight for patient safety and a patient-centered approach are critical to biosimilars policy.

elderly man sitting in chair receiving chemotherapy

Training program

This self-paced 6-hour interactive training program offers 18 educational videos covering the biosimilars basics, key policy issues, and how to take action. Speakers are biosimilar thought leaders including medical professionals, patient advocates, and policy experts. The training program includes the Biosimilars Patient Advocacy toolkit with fact sheets, sample position statements and letters, and tips on bringing the patient voice to biosimilar policy.

The Biosimilars Training Program is available on demand.